All In Biotech

Drug Trial Radar · NCT03572933

Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment

Last checked: Nov 19, 2026Latest source record: Apr 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Jun 30, 2018

Primary completion

Jul 31, 2020

Study completion May 28, 2021

Sponsor

Lead sponsor
Marinus PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.

Conditions

  • CDKL5 Deficiency Disorder

Interventions

  • ganaxoloneDrug

    active drug

  • PlaceboDrug

    inactive

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of 28-day Seizure Frequency for Major Motor Seizure TypesTime frame: End of the double-blind 17 week treatment period

Locations

36 sites in 8 countries. Site status is shown where the registry gives one.

  • Marinus Research Site

    Phoenix, Arizona

  • Marinus Research Site

    Los Angeles, California

  • Marinus Research Site

    Aurora, Colorado

  • Marinus Research Site

    Gulf Breeze, Florida

  • Marinus Research Site

    Orlando, Florida

  • Marinus Research Site

    Norcross, Georgia

  • Marinus Research Site

    Chicago, Illinois

  • Marinus Research Site

    Iowa City, Iowa

  • Marinus Research Site

    Boston, Massachusetts

  • Marinus Research Site

    Rochester, Minnesota

  • Marinus Research Site

    St Louis, Missouri

  • Marinus Research Site

    Livingston, New Jersey

  • Marinus Research Site

    Cleveland, Ohio

  • Marinus Research Site

    Philadelphia, Pennsylvania

  • Marinus Research Site

    Pittsburgh, Pennsylvania

  • Marinus Research Site

    Fort Worth, Texas

  • Marinus Research Site

    Houston, Texas

  • Marinus Research Site

    Brisbane, Queensland, Australia

  • Marinus Research Site

    Heidelberg, Victoria, Australia

  • Marinus Research Site

    Melbourne, Victoria, Australia

  • Marinus Research Site

    Paris, France

  • Marinus Research Site

    Ramat Gan, Israel

  • Marinus Research Site

    Florence, Italy

  • Marinus Research Site

    Milan, Italy

  • Marinus Research Site

    Pavia, Italy

  • Marinus Research Site

    Roma, Italy

  • Marinus Research Site

    Verona, Italy

  • Marinus Research Site

    Bydgoszcz, Poland

  • Marinus Research Site

    Krakow, Poland

  • Marinus Research Site

    Moscow, Russia

  • Marinus Research Site

    Nizhny Novgorod, Russia

  • Marinus Research Site

    Novosibirsk, Russia

  • Marinus Research Site

    Birmingham, United Kingdom

  • Marinus Research Site

    Bristol, United Kingdom

  • Marinus Research Facility

    Glasgow, United Kingdom

  • Marinus Research Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.